Ruti Aga's Six-Year Ban: How a Forged Prescription Turned a Two-Year Sanction into Career Death

If you read the Athletics Integrity Unit (AIU) statement released on Thursday with any care, one date keeps returning: 10 September. Ruti Aga's six-year ban runs from that date, and her provisional suspension had already been running from it too. That is not a reduction, it is arithmetic. The real story is that a 32-year-old marathoner with a 2026 Tokyo Marathon title and three World Marathon Major second places can now only contemplate a comeback at roughly 38 — which makes the sanction functionally a lifetime ban. But what stops me in this case is the prescription itself, and who wrote it; to see that clearly I had to go back to the frame the AIU itself put on record.

The medical-governance sample that came from China in March

According to the AIU, Aga won a half marathon in China in March, and the sample taken after that race returned methylprednisolone. I want to log a technical correction here, because most versions of this story are repeating an error that distorts the whole case. Methylprednisolone is not an anabolic steroid; it is a glucocorticoid, class S9 on the WADA Prohibited List, and it is prohibited in-competition only — by injection, oral or rectal routes. A therapeutic knee injection given out of competition is entirely legal. The case turns on when and by which route the drug was given, and whether residue remained in competition. In road racing that distinction is sharper still, because a road race's competition period opens at 23:59 the day before the race — so an injection given days earlier can still be caught.

That is where the story stops being about sport and becomes a story about medicine and paperwork. Aga's defence cited a knee injury. I will not dismiss that out of hand — intra-articular or peri-articular treatment for knee synovitis is standard sports-medicine practice in distance runners. What the AIU investigation produced was not a medical story but a forgery story: a prescription carrying the stamp of a clinic that did not exist, written by a family member with no medical registration.

Two years plus four, and one prescription standing in between

The sanction arithmetic is plain: two years for the presence violation, four for tampering — six in total. That structure tells us the panel did not find aggravating intent behind the substance charge, hence the standard two years, but held the athlete fully culpable for the fabricated document and the misleading interview statements. In my experience with World Athletics and AIU road-racing cases, that second charge has become the most common of all — the substance caught first, the concealment attempt second, and the sanction roughly tripled.

The sentence in the AIU statement that matters most to me is the family member's claim that an "old prescription pad from a former workplace" was used — and the clinic's explicit disavowal of it. Three independent verification points failed here, and that is the real diagnosis of this case. With a credentialed team physician, with documented medical records, the defence path was open: establish timing and route, demonstrate necessity, and the sanction might have collapsed into a reprimand or a short period, with no tampering charge at all. The forged document closed the one route that could have worked.

This is not an isolated event in the East African road-racing circuit Aga moved through. Her career did not begin at the 2026 Berlin Marathon second place, it peaked there; and after the 2026 Tokyo title her pattern was selective Majors plus Asian label races — especially the Chinese half-marathon circuit — for appearance fees. I have watched that tier for years: the economic bridge between the big Majors and the smaller labels, where talent density is high and, increasingly, testing density is too. The appearance-fee economy and the testing economy are colliding on the same races.

An easy defence, an expensive stubbornness

Here is the counter-intuitive conclusion, and I will put it plainly. At the level of the substance, this case began as a situation with a legitimate defence — a question of protocol, route and timing. But the day someone decided to manufacture a prescription, the case stopped being about sport and became a document offence. During the Tokyo Olympics I learned from watching 18 warm-up throws that an athlete's body tells the truth and a press release often does not; here it is inverted — the body probably told the truth about the knee, but the paper made that truth unusable.

Some observers will argue that six years is disproportionate for a glucocorticoid with no proven endurance benefit, and the number will be cited both as proof of AIU rigour and as evidence of uneven enforcement against African road runners. My objection is not to the substance but to the scope of the ruling — the panel kept tampering separate, so both things must be held together: the substance case was ordinary, the attempt to conceal it made it extraordinary. Since the 2026 CAS-confirmed bans on six women, people here read every suspension through a lens of suspicion; the question here is not one athlete's intent but the system that pushes an injured runner toward forged paper instead of lawful treatment.

What survives Aga — and whose response we are waiting for

Her record will split. The March race result and prize money in China will almost certainly be annulled, future ranking points will go, while the 2026 Tokyo title and the three Major second places remain on the record as achievements of their period — provided the investigation does not establish earlier use, which the statement does not mention. What the AIU did not say is whether her agent or management had any role in the forged document, and no statement has come from the Ethiopian federation.

For me this case leaves a question I will keep open deliberately: is the purpose of the sanction simply to prove a document fake, or to fix the system in which an injured marathoner has no lawful path to treatment and only an old prescription pad? Until that is answered, the next Aga will be sitting at the same table after another Chinese label race — and at that point six years will be not a lesson but an expense.